David C Kem

US Patent:

20050079178, Apr 14, 2005

Filed:

Aug 26, 2004

Appl. No.:

10/927616

Inventors:

David Kem - Edmond OK, US
Eugene Patterson - Oklahoma City OK, US

International Classification:

A61K039/395
A61K031/415

US Classification:

424145100, 514406000

Abstract:

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and/or decreasing the incidence and/or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and/or β-ARK expression.

US Patent:

20080161241, Jul 3, 2008

Filed:

Sep 11, 2007

Appl. No.:

11/900237

Inventors:

David C. Kem - Edmond OK, US
Eugene Patterson - Oklahoma City OK, US

International Classification:

A61K 38/17
A61K 31/69
A61P 9/10

US Classification:

514 12, 514 64

Abstract:

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and/or decreasing the incidence and/or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and/or β-ARK expression.

US Patent:

20210236597, Aug 5, 2021

Filed:

Feb 2, 2021

Appl. No.:

17/165070

Inventors:

- Norman OK, US
David C. KEM - Edmond OK, US

International Classification:

A61K 38/17
C07K 14/72
G01N 33/566

Abstract:

Compounds, compositions, and delivery devices, for treating and diagnosing conditions and diseases associated with activation of the gonadotropin releasing hormone receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain non-limiting embodiments include peptides which comprise D-amino acids (D-amino acid peptides) which are able to bind with high affinity to GnRHR AAbs.

US Patent:

20200165318, May 28, 2020

Filed:

Nov 27, 2019

Appl. No.:

16/697589

Inventors:

- Norman OK, US
David C. Kem - Edmond OK, US

International Classification:

C07K 14/72
A61K 39/00
A61K 38/08
A61K 38/10
A61K 9/00
A61K 9/06
A61K 9/08
C07K 7/06

Abstract:

Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.

US Patent:

20180291085, Oct 11, 2018

Filed:

Jun 1, 2018

Appl. No.:

15/995812

Inventors:

- Norman OK, US
David C. Kem - Edmond OK, US

International Classification:

C07K 14/72
A61K 9/08
A61K 9/06
A61K 9/00
A61K 39/00
C07K 7/06
A61K 38/10
A61K 38/08

Abstract:

Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease condition or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.

US Patent:

20160222084, Aug 4, 2016

Filed:

Mar 14, 2014

Appl. No.:

14/776855

Inventors:

- Norman OK, US
David C. Kem - Edmond OK, US

International Classification:

C07K 14/72
C07K 7/06

Abstract:

Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease condition or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.